论文部分内容阅读
目的探讨内皮型一氧化氮合酶(eNOS)基因G894T多态性与替米沙坦降压效果的相关性。方法轻、中度原发性高血压(以下简称高血压)患者75例服替米沙坦单药4周,观察临床疗效,并采用多聚酶链式反应-限制性内切酶片段长度多态性方法(PCR-RFLP)分析患者eNOS基因G894T的基因型。结果高血压患者eNOS基因G894T3种基因型分别为GG44.0%、GT41.3%、TT14.7%,其中G、T等位基因频率分别为64.7%和35.3%。治疗前GG+GT基因型组和GG基因型组患者的收缩压、舒张压和平均动脉压比较差异均无统计学意义。治疗4周后,GT+TT基因型组患者舒张压下降的幅度〔(6.1±7.3)mmHg(1mmHg=0.133kPa)〕大于GG基因型组〔(4.0±8.0)mmHg〕,但差异无统计学意义(P=0.624),收缩压下降的幅度〔(7.7±12.8)mmHg〕比GG基因型组〔(9.6±19.0)mmHg〕小,差异亦无统计学意义(P=0.623)。结论在本组高血压人群中未发现eNOS基因G894T多态性与血管紧张素Ⅱ受体拮抗剂替米沙坦类药物降压效果的相关性。
Objective To investigate the relationship between the polymorphism of endothelial nitric oxide synthase (eNOS) gene G894T and the antihypertensive effect of telmisartan. Methods Seventy - five patients with mild to moderate essential hypertension (hereinafter referred to as hypertension) were treated with telmisartan monotherapy for 4 weeks. The clinical efficacy was observed. The polymerase chain reaction - restriction fragment length polymorphism Methods Genotypes of eNOS gene G894T were analyzed by PCR-RFLP. Results The genotypes of G894T3 in patients with hypertension were GG44.0%, GT41.3% and TT14.7%, respectively. The frequencies of G and T alleles were 64.7% and 35.3% respectively. There was no significant difference in systolic blood pressure, diastolic blood pressure and mean arterial pressure between GG + GT genotype group and GG genotype group before treatment. After 4 weeks of treatment, the decrease in diastolic blood pressure in patients with GT + TT genotype was (6.1 ± 7.3) mmHg (1 mmHg = 0.133 kPa) greater than that in GG genotype patients (4.0 ± 8.0) mmHg, but the difference was not statistically significant (P = 0.624). The decrease of systolic blood pressure (7.7 ± 12.8 mmHg) was smaller than that of GG genotype (9.6 ± 19.0 mmHg), and the difference was not statistically significant (P = 0.623). Conclusion There is no correlation between eNOS gene G894T polymorphism and antihypertensive effect of telmisartan, an angiotensin Ⅱ receptor antagonist, in this hypertensive population.